President of $CTSH in Americas sells 1,728 shares in insider sale.

In a recent SEC filing, it was disclosed that Surya Gummadi, serving as the President – Americas of $CTSH, executed a transaction involving 1,728 shares of the company on 02-02-2026, yielding an approximate value of $143,523. This sale accounted for about 6.3% of their holdings in this particular stock class, leading to their current ownership of 25,641 shares of this category of $CTSH stock.

Over a span of the last 6 months, insiders at $CTSH engaged in a total of 21 trades involving the company’s stock. Notably, none of these transactions constituted purchases, with all 21 transactions being sales. Notable among these sales are those conducted by key figures within the company, including Michael Patsalos-Fox, Surya Gummadi, John Sunshin Kim, Ravi Kumar Singisetti, and Alina Kerdman. These insiders collectively sold off substantial shares, with Patsalos-Fox executing 8 sales amounting to 31,965 shares valuing at $2,607,417, and Gummadi partaking in 4 sales totaling 22,728 shares with an estimative worth of $1,797,954.

Turning attention to hedge fund activities related to $CTSH, it is notable that a significant number of institutional investors made alterations to their holdings. In fact, 486 institutional investors opted to increase their shares of $CTSH stock in their portfolios, while 497 chose to decrease their positions during the most recent quarter. Noteworthy adjustments included UBS AM, a business unit of UBS Asset Management Americas LLC, adding 3,949,442 shares (representing a 79.4% increase) in Q3 2025 valued at $264,889,074. Conversely, Wellington Management Group LLP reduced their shares by 3,278,541 (-42.1%) in Q3 2025, corelating to an estimated value of $219,891,744.

In terms of revenue, $CTSH reported revenues of $5.3B in Q4 2025, indicating a 4.94% surge from the corresponding period in the prior year. This represents a substantial financial growth, which can be further tracked on company-specific platforms that provide comprehensive financial insights.

Regarding analyst ratings, recent reports from Wall Street analysts have been positive for $CTSH, as 4 firms issued buy ratings on the stock during the last few months. These ratings were issued by notable firms such as William Blair, Wells Fargo, JP Morgan, and Guggenheim, all signaling encouraging sentiments towards $CTSH. This showcases a favorable outlook towards the company’s performance in the industry.

Multiple analysts have also put forth price targets for $CTSH, with a median target of $86.0 from 7 analysts offering price predictions within the last 6 months. Noteworthy targets include Jonathan Lee from Guggenheim setting a target price of $100.0, and Bryan Keane from Citigroup predicting a target price of $86.0, among others highlighting the growth potential of the company in the market. The assessed targets and predictions serve as crucial indicators for potential investors seeking insights into the company’s trajectory and performance outlook.

In conclusion, the recent activities and transactions surrounding $CTSH indicate a dynamic landscape of movement within the company, with insider trades, hedge fund activities, revenue reports, analyst ratings, and price targets all pointing towards a promising future for the organization within the market.